Tag:
Human Genome Sciences
Latest Headlines
Latest Headlines
GSK gambles on biotech partners after dubious M&A deal
GlaxoSmithKline ($GSK) has shown in a series of M&A and investment moves that the London-based drug giant prefers to bet on known commodities--existing biotech partners. Bloomberg analyzed GSK's strategy and speculates that the company could pick one of its collaborators as a future buyout target.
GSK tweaks Human Genome bid to include poison pill antidote
The two companies are at loggerheads over a deal. HGS says that Glaxo simply waited until its share price hit rock bottom before offering a bargain basement price for the maker of Benlysta. GSK says it's being more than fair.
HGS puts 'poison pill' in its arsenal against GSK
Human Genome Sciences has added a poison pill to its portfolio as it tries to fend off the hostile takeover by its longtime partner GlaxoSmithKline.
HGS faces skeptics as it boasts of a crowded bargaining table
Human Genome Sciences has prescribed a poison pill for GlaxoSmithKline's hostile takeover bid.
Glaxo can nail HGS buy with slightly bigger bid, analysts say
A $15 bid may win over investors, in comparison with the current $13.
Glaxo goes hostile on HGS with $2.6B bid
Prepare yourself for a drawn-out buyout battle--and lots of debate about the lupus treatment Benlysta.
GSK raises fists in $2.6B hostile bid for Human Genome Sciences
The gloves are off. GlaxoSmithKline has mounted a hostile offer for its long-time partner Human Genome Sciences.
Pharma continues parachute-building for patent cliff
Last month was a big one for pharma dealmaking, as anyone following the industry well knows. The list of deals, bids and potential deals is long--$33 billion long.
Pharma rides a wave of targeted M&A deals
The reasons behind the dealmaking aren't new: Established markets are slowing down as emerging markets speed up, sending companies shopping in the developing world.
2012: Year of the dealmaker in biopharma
It's no coincidence that two of today's top 5 biotech stories involve late-stage drugs that look increasingly attractive to potential buyers.
